Fibrocell's Wrinkle Drug Underlines Challenges Of Seeking Aesthetic Claims
Executive Summary
An FDA advisory committee made very clear that the bar should be much higher for novel products proposed for aesthetic indications than for drugs to treat diseases during the Oct. 9 review of Fibrocell Science's wrinkle therapy Laviv (azfibrocel-T)